Research Article Open Access

Ribavirin Plus Therapy in Covid-19-A Single-Center Experience

Budha Oinam Singh1, Gaurav Chikara2, Prasan Kumar Panda1, Yogesh Arvind Bahurupi3, Sarama Saha4 and Venkatesh Srinivasa Pai1
  • 1 Department of Internal Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  • 2 Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  • 3 Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Rishikesh, India
  • 4 Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh, India

Abstract

COVID-19 infection has a similar clinical spectrum of disease presentation such as SARS and MERS in the past. These led to the assumption of the possibility to treat COVID-19 infection with antivirals which had been used to treat SARS and MERS. A retrospective analysis was done in symptomatic adult patients of COVID-19 infection to explore whether ribavirin antiviral combinations reduce the need for both Noninvasive and Invasive Ventilation (NIV/IV) in the treatment of COVID-19 infections. Cohort A consisted of 40 patients who received the standard therapy and Cohort B of 61 patients who received the ribavirin plus therapy (Ribavirin with Hydroxychloroquine or Lopinavir/Ritonavir). Cohort A required NIV and IV each in 12.5% of patients while Cohort B required the same in 18.03 and 16.39% of patients respectively (p = 0.456). There was a similar trend of reduction of organ dysfunctions with time in cohort A compared to B. The study concluded there was no statistically significant reduction in the need for ventilation (non-invasive/invasive) and the development of multi-organ dysfunction in COVID-19 patients treated with ribavirin plus therapy, rather clinically standard therapy was better in all aspects.

American Journal of Pharmacology and Toxicology
Volume 18 No. 1, 2023, 1-7

DOI: https://doi.org/10.3844/ajptsp.2023.1.7

Submitted On: 10 March 2023 Published On: 25 July 2023

How to Cite: Singh, B. O., Chikara, G., Panda, P. K., Bahurupi, Y. A., Saha, S. & Pai, V. S. (2023). Ribavirin Plus Therapy in Covid-19-A Single-Center Experience. American Journal of Pharmacology and Toxicology, 18(1), 1-7. https://doi.org/10.3844/ajptsp.2023.1.7

  • 2,025 Views
  • 1,394 Downloads
  • 0 Citations

Download

Keywords

  • Antivirals
  • Coronavirus Disease 2019
  • Hydroxychloroquine
  • Lopinavir/Ritonavir
  • Multi-Organ Dysfunction
  • Ribavirin